{"id":"aevi-001","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4303484","moleculeType":"Small molecule","molecularWeight":"548.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the PI3K/AKT pathway, which is involved in cell growth and survival. This inhibition can lead to the death of cancer cells. AEVI-001 is being investigated as a potential treatment for various types of cancer.","oneSentence":"AEVI-001 is a small molecule drug that targets the PI3K/AKT pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:04.831Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute lymphoblastic leukemia (ALL)"}]},"trialDetails":[{"nctId":"NCT03609619","phase":"PHASE2","title":"PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations","status":"COMPLETED","sponsor":"Aevi Genomic Medicine, LLC, a Cerecor company","startDate":"2018-08-17","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":109},{"nctId":"NCT03265119","phase":"PHASE2","title":"PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations","status":"COMPLETED","sponsor":"Aevi Genomic Medicine, LLC, a Cerecor company","startDate":"2017-08-28","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":69},{"nctId":"NCT03006367","phase":"PHASE1","title":"Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD","status":"COMPLETED","sponsor":"Aevi Genomic Medicine, LLC, a Cerecor company","startDate":"2017-01-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MDGN-001","NFC-1"],"phase":"phase_2","status":"active","brandName":"AEVI-001","genericName":"AEVI-001","companyName":"Aevi Genomic Medicine, LLC, a Cerecor company","companyId":"aevi-genomic-medicine-llc-a-cerecor-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AEVI-001 is a small molecule drug that targets the PI3K/AKT pathway. Used for Relapsed or refractory acute lymphoblastic leukemia (ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}